10.1016/j.ejmech.2015.05.036
The study presents the design, synthesis, and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring a morpholine moiety, which were developed as inhibitors of PI3Kα, a key enzyme in cellular survival and apoptosis pathways, often aberrantly activated in cancer. The chemicals used in the study include a series of synthesized compounds (6a-d, 8a-d, 10a,b, and 12a-e) that serve as potential PI3Kα inhibitors. These compounds were designed based on the pharmacophore model for PI3K p110α inhibitors and were tested for their inhibitory activity and selectivity towards different PI3K isoforms. The purpose of these chemicals is to potentially provide a new avenue for cancer therapy by targeting the PI3K signaling pathway, with the aim of inhibiting uncontrolled cell proliferation and migration associated with tumor formation. The study also involved molecular docking simulations to predict the binding affinity and mode of these compounds within the p110α active site, and their cytotoxic activities were evaluated against specific cancer cell lines.